British Journal of Haematology — Allan JN, Shanafelt T, Wiestner A, et al. | December 07, 2021
This large, pooled, multi-study data set results demonstrate that first-line ibrutinib-based therapy confers promising long-term outcomes in patients with chronic lymphocytic leukemia (CLL) bearing TP53 aberrations.
This is a pooled analysis across four studies, to assess long-term efficacy and safety of first-line ibrutinib-based therapy in CLL patients having TP53 aberrations [del(17p) or TP53 mutation].
Participants were 89 patients with TP53 aberrations undergoing first-line therapy with single-agent ibrutinib (n = 45) or ibrutinib plus an anti-CD20 antibody (n = 44).
Median progression-free survival was not reached with a median observation span of 49·8 months (range, 0·1–95·9).
At four years, progression-free and overall survival rates were 79% and 88%, respectively.
An overall response rate of 93% (complete response in 39%) was achieved.
No new safety signals were found.